Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Squamous Cell Carcinoma 12 Esophageal Neoplasms 9 Uterine Cervical Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Lymphatic Metastasis 2 Uterine Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Solid Tumor Cancer 1 Recurrence 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ductal, Breast 1 Breast Neoplasms 1

Interventions

Carboplatin 339 Cisplatin 238 Paclitaxel 203 Radiotherapy 194 Pemetrexed 187 Docetaxel 169 Gemcitabine 157 pembrolizumab 140 Erlotinib Hydrochloride 107 Etoposide 98 Magnetic Resonance Spectroscopy 92 Bevacizumab 91 Specimen Handling 76 Nivolumab 73 Radiosurgery 71 durvalumab 69 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 49 Irinotecan 42 atezolizumab 41 Topotecan 39 Radiation 39 Biopsy 39 Cyclophosphamide 38 Standard of Care 37 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × TP protocol × Clear all

NCT00801736 2013-12-10

ET

University College, London

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡